However, contrasting findings were reported in another study, where the addition of carboplatin to cabazitaxel was not beneficial for the 36 men (40%) with BRCA2 somatic alterations detected in circulating tumor DNA16. The gene discussed is BRCA2; the disease is neoplasm.